Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Recruiting · NCT06342466 · Registry updated 2024-12-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, primary systemic amyloidosis, proteostasis deficiencies | Recruiting | Phase 2 | 2024-12-30 | NCT06342466 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jin Lu, MD | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University People's Hospital | Beijing | China | 146 |